Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Post-Market Trading 11-22 19:17:44 EST

55.68

+0.14

+0.25%

盘后55.68

+0.000.00%

16:48 EST

High56.82	Low54.73	Vol456.10K
Open55.78	D1 Closing55.54	Amplitude3.76%
Mkt Cap3.18B	Tradable Cap2.81B	Total Shares57.03M
T/O25.49M	T/O Rate0.90%	Tradable Shares50.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":55.68,"timestamp":1732309200000,"preClose":55.54,"halted":0,"volume":456102,"hourTrading":{"tag":"盘后","latestPrice":55.68,"preClose":55.68,"latestTime":"16:48 EST","volume":38661,"amount":2152642.740255,"timestamp":1732312118880},"delay":0,"floatShares":50522137,"shares":57030195,"eps":11.798295,"marketStatus":"Post-Market Trading","change":0.14,"latestTime":"11-22 19:17:44 EST","open":55.78,"high":56.82,"low":54.73,"amount":25487744.186952,"amplitude":0.037631,"askPrice":66.16,"askSize":100,"bidPrice":50,"bidSize":2,"shortable":3,"etf":0,"ttmEps":11.798295,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":55.54,"preHourTrading":{"tag":"盘前","latestPrice":56.4,"preClose":55.54,"latestTime":"09:14 EST","volume":73,"amount":4047.8397800000002,"timestamp":1732284861769},"postHourTrading":{"tag":"盘后","latestPrice":55.68,"preClose":55.68,"latestTime":"16:48 EST","volume":38661,"amount":2152642.740255,"timestamp":1732312118880},"volumeRatio":0.846282,"impliedVol":0.5348,"impliedVolPercentile":0.5635},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2482269517","title":"Leerink Partners Sticks to Their Hold Rating for Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482269517","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482269517?lang=en_us&edition=fundamental","pubTime":"2024-11-12 15:48","pubTimestamp":1731397722,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) yesterday. The company’s shares closed yes...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-their-hold-rating-for-agios-pharma-agio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-their-hold-rating-for-agios-pharma-agio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"gpt_icon":0},{"id":"1142227548","title":"Stock Track | Agios Pharmaceuticals Soars 5% Despite Concerns Over Earnings Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=1142227548","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142227548?lang=en_us&edition=fundamental","pubTime":"2024-11-08 04:36","pubTimestamp":1731011793,"startTime":"0","endTime":"0","summary":"Shares of Agios Pharmaceuticals Inc.  rose 5% on Wednesday, even as a financial analysis raised concerns about the quality of the pharmaceutical company's recent earnings report. The stock surge came despite a warning from Simply Wall St. that Agios' profit was boosted by unusual items and did not match its free cash flow.According to the analysis, Agios had an accrual ratio of 2.33 for the year to September 2024, indicating that its profit significantly exceeded its free cash flow. The company ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Agios Pharmaceuticals Soars 5% Despite Concerns Over Earnings Quality","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AGIO"],"gpt_icon":0},{"id":"2481059269","title":"Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=2481059269","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481059269?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:57","pubTimestamp":1730980663,"startTime":"0","endTime":"0","summary":"Even though Agios Pharmaceuticals, Inc.  posted strong earnings recently, the stock hasn't reacted in a large way. We decided to have a deeper look, and we believe that investors might be worried about several concerning factors that we found.NasdaqGS:AGIO Earnings and Revenue History November 7th 2024. One key financial ratio used to measure how well a company converts its profit to free cash flow  is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. That's because some academic studies have suggested that high accruals rat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-nasdaq-agio-posting-115743963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","AGIO",".IXIC"],"gpt_icon":0},{"id":"2481000605","title":"Agios Pharmaceuticals to present new data on mitapivat, tebapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2481000605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481000605?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:31","pubTimestamp":1730817098,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in oral and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-to-present-new-data-on-mitapivat-tebapivat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-to-present-new-data-on-mitapivat-tebapivat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2481178502","title":"Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2481178502","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481178502?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:05","pubTimestamp":1730815500,"startTime":"0","endTime":"0","summary":"– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –。– Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published –。– Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 –。Key presentations and publications at ASH 2024 will include:. An oral presentation on results from the Phase 3 ENERGIZE-T study evaluating mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia versus placebo. Alongside the positive results from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent alpha- or beta-thalassemia previously presented at the 2024 European Hematology Association  Congress, these data support mitapivat’s potential as an oral, disease-modifying therapy across the full range of patients with thalassemia regardless of transfusion","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-present-data-mitapivat-tebapivat-140500632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASH","BK4139","PT","BK4109","BK4166","LU2463526074.USD","PK","AGIO","BK4218","BK4181"],"gpt_icon":0},{"id":"2480834521","title":"Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2480834521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480834521?lang=en_us&edition=fundamental","pubTime":"2024-11-02 00:43","pubTimestamp":1730479380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 12:43 ET (16:43 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2480326608","title":"AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2480326608","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480326608?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:47","pubTimestamp":1730472420,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. AGIO reported earnings of $16.22 per share for the third quarter of2024, which missed the Zacks Consensus Estimate of $16.69. In the year-ago quarter, the company had reported a loss of $1.64 per share.The abovementioned earnings included a gain on the sale of contingent payments and a milestone payment from a gain on the sale of the oncology business. Excluding these items, the company incurred a loss of 15 cents per share.In August 2024, the FDA approved vorasidenib for a brain tumor called IDH-mutant diffuse glioma. Per the terms of the sale executed between Agios and Servier, the latter was to pay a milestone payment of $200 million to Agios for this approval. In May 2024, Agios entered into a deal with Royalty Pharma to sell its royalty rights on potential net sales of vorasidenib in exchange for an upfront payment of $905 million.In the third quarter, AGIO reported revenues of $9 million, which came in line with the Zacks Consensus Estimate. In the yea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-q3-earnings-miss-mark-144700178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2480749882","title":"Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2480749882","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480749882?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:30","pubTimestamp":1730471400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 10:30 ET (14:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2480188254","title":"Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2480188254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480188254?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:07","pubTimestamp":1730470031,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company’s shares open...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-agios-pharma-agio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-agios-pharma-agio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","AGIO"],"gpt_icon":0},{"id":"2480836930","title":"Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480836930","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480836930?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:40","pubTimestamp":1730468411,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ADC Therapeutics SA  one of those stocks right now?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.ADC Therapeutics SA is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 .Agios Pharmaceuticals  is an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-adct-stock-outpacing-134011268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","AGIO","BK4231","BK4080","ADC","BK4139","ADCT"],"gpt_icon":0},{"id":"2480909885","title":"Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2480909885","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480909885?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:57","pubTimestamp":1730465834,"startTime":"0","endTime":"0","summary":"NasdaqGS:AGIO Earnings and Revenue Growth November 1st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 5.7%. Earnings per share  exceeded analyst estimates by 87%.Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 1.5% from a week ago.You still need to take note of risks, for example - Agios Pharmaceuticals has   2 warning signs    we think you should know about.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-third-quarter-2024-125714675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2480087680","title":"Agios Pharma (AGIO) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2480087680","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480087680?lang=en_us&edition=fundamental","pubTime":"2024-11-01 18:30","pubTimestamp":1730457026,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-receives-a-buy-from-rbc-capital-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-receives-a-buy-from-rbc-capital-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGIO","BK4207"],"gpt_icon":0},{"id":"2480201760","title":"Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2480201760","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480201760?lang=en_us&edition=fundamental","pubTime":"2024-11-01 15:03","pubTimestamp":1730444610,"startTime":"0","endTime":"0","summary":"Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023.Cash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024.Milestone Payments: Received $1.1 billion following FDA approval of vorasidenib.R&D Expenses: $72.5 million for Q3 2024, a decrease of $9.4 million from Q3 2023.SG&A Expenses: $38.5 million for Q3 2024, an increase of $12.7 million from Q3 2023.Cost of Sales: $0.8 million for Q3 2024.Patient Enrollment: 211 patients completed prescription enrollment for Pyrukynd, with 127 net patients on therapy.GuruFocus has detected 5 Warning Signs with AGIO.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Agios Pharmaceuticals Inc  received $1.1 billion in milestone payments following FDA approval of vorasidenib, strengthening its cash position.The company received FDA orphan drug designation for Tebapivat for the treatment of myelodysplastic syndromes , highlighting its p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BEiT2TttpVN.QEvEptyIpA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/b49f881031f5edba4200c26f78a0f1fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BEiT2TttpVN.QEvEptyIpA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/b49f881031f5edba4200c26f78a0f1fb"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-070330912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2480497610","title":"Agios Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2480497610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480497610?lang=en_us&edition=fundamental","pubTime":"2024-11-01 11:32","pubTimestamp":1730431963,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary  Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly adjusted loss of $2.42 per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nL8N3M80C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2479348240","title":"Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2479348240","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479348240?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:34","pubTimestamp":1730385285,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  shares fell 2.7% in recent Thursday trading after the company's Q3 revenue fell below market expectations.The biopharmaceutical company reported Q3 net income Thursday of $16.22 per diluted share, compared with a loss of $1.64 a year earlier.Analysts polled by Capital IQ expected earnings of $8.69 per share.Revenue for the quarter ended Sept. 30 was about $9.0 million, up from $7.4 million a year earlier.Analysts surveyed by Capital IQ expected $9.5 million.Price: 45.05, Change: -1.25, Percent Change: -2.70","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO"],"gpt_icon":0},{"id":"1159094832","title":"Stock Track | Agios Pharmaceuticals Plunges on Disappointing Q3 Results, Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1159094832","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159094832?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:46","pubTimestamp":1730382414,"startTime":"0","endTime":"0","summary":"Shares of Agios Pharmaceuticals Inc.  plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' estimates on both earnings and revenue.The Cambridge, Massachusetts-based company reported earnings of $4.20 per share for the quarter, significantly missing the Zacks Consensus Estimate of $16.69 per share. Revenue for the quarter came in at $8.96 million, falling short of analysts' expectations of $9.46 million.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AGIO"],"gpt_icon":0},{"id":"2479234087","title":"Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479234087","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479234087?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:45","pubTimestamp":1730375109,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -74.84%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.58 per share when it actually produced a loss of $1.69, delivering a surprise of -6.96%.Agios Pharmaceuticals , which belongs to the Zacks Medical - Products industry, posted revenues of $8.96 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 4.29%. This compares to year-ago revenues of $7.4 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Agios Pharmaceuticals shares have added about 107.9% since the beginning of the year versus the S&P 500's gain of 21.9%.While Agios Pharmaceuticals has outperformed the mark","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-agio-misses-q3-114509816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2479470210","title":"BRIEF-Agios Reports Business Highlights And Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2479470210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479470210?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:21","pubTimestamp":1730373712,"startTime":"0","endTime":"0","summary":"Oct 31 (Reuters) - Agios Pharmaceuticals Inc   :   * AGIOS REPORTS BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS   * AGIOS PHARMACEUTICALS INC: QTRLY EPS $16.22Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2479370180","title":"Agios Pharmaceuticals: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2479370180","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479370180?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:42","pubTimestamp":1730371339,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass.  — CAMBRIDGE, Mass.  — Agios Pharmaceuticals Inc.  on Thursday reported third-quarter net income of $947.9 million, after reporting a loss in the same period a year earlier.The Cambridge, Massachusetts-based company said it had net income of $16.22 per share. Earnings, adjusted for non-recurring gains, came to $4.20 per share.The biopharmaceutical company posted revenue of $9 million in the period, which did not meet Street forecasts. Five analysts surveyed by Zacks expected $9.4 million.Agios Pharmaceuticals shares have more than doubled since the beginning of the year. The stock has more than doubled in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-q3-earnings-snapshot-104219006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGIO"],"gpt_icon":0},{"id":"2479770593","title":"Agios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2479770593","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479770593?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:32","pubTimestamp":1730370771,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly sales of $8.96 million which missed the analyst consensus estimate of $9.46 million by 5.25 percent.  This is a 21.15 percent increase over sales of $7.40 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41648076/agios-pharmaceuticals-q3-sales-8-96m-miss-9-46m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Agios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":0.2239},{"period":"3month","weight":0.2016},{"period":"6month","weight":0.7632},{"period":"1year","weight":1.5291},{"period":"ytd","weight":1.4939}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.818182,"avgChangeRate":0.042769},{"month":2,"riseRate":0.636364,"avgChangeRate":0.059258},{"month":3,"riseRate":0.545455,"avgChangeRate":0.003251},{"month":4,"riseRate":0.545455,"avgChangeRate":0.006144},{"month":5,"riseRate":0.545455,"avgChangeRate":0.049654},{"month":6,"riseRate":0.636364,"avgChangeRate":0.046688},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.024214},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046002},{"month":9,"riseRate":0.5,"avgChangeRate":0.041136},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.014099},{"month":11,"riseRate":0.666667,"avgChangeRate":0.055954},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.013921}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}